Caribou Biosciences is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats genome-editing biopharmaceutical company focused on developing therapies for patients with devastating diseases. Co.'s CB-010 is a clinical-stage allogeneic anti-CD19 chimeric antigen receptor (CAR)-T (CAR-T) cell therapy with programmed cell death protein 1 removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. Co.'s CB-011 is an allogeneic CAR-T cell therapy that is an anti-B cell maturation antigen CAR-T cell therapy incorporating an immune cloaking approach. Co.'s CB-012 is an allogeneic CAR-T cell therapy targeting C-type lectin-like molecule-1. The CRBU average annual return since 2021 is shown above.
The Average Annual Return on the CRBU average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CRBU average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CRBU average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|